重度哮喘接受美泊利珠单抗治疗前两年的结局
研究关注重度哮喘患者接受美泊利珠单抗治疗第二年的持续情况。结果显示30%的患者在治疗第二年停用美泊利珠单抗;持续应答者在开始治疗前具有较低的血嗜酸性粒细胞和较好的哮喘控制问卷评分。
要点
- 30%的患者在美泊利珠单抗治疗第二年停药。
- 持续应答者治疗前血嗜酸性粒细胞较低。
- 持续应答者治疗前哮喘控制问卷评分较好。
核心结论
- 30%的患者在治疗第二年停用美泊利珠单抗。
- 持续应答者开始治疗前血嗜酸性粒细胞较低且哮喘控制问卷评分较好。
主要发现
- 30%的患者在治疗第二年停用美泊利珠单抗。
- 持续应答者开始治疗前血嗜酸性粒细胞较低。
- 持续应答者开始治疗前哮喘控制问卷评分较好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study found that 30% of patients stopped mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab. https://bit.ly/3ChWN63 Mepolizumab was the first anti-interleukin-5 (anti-IL-5) monoclonal antibody licensed for the treatment of severe asthma, recommended as add-on treatment in patients with frequent exacerbations or requiring maintenance oral corticosteroids (OCS) despite optimal inhaled therapy [1, 2]. In clinical trials it reduced exacerbation rates and OCS use, and improved lung function, asthma control and health-related quality of life over the first year of treatment [3–6]. Current guidance states that anti-IL-5 biologics should be continued long term if benefit is demonstrated over the first year, yet little is known about whether initial responses are sustained, or whether they can be predicted by clinical characteristics.
引用
- Elsey L, Pantin T, Holmes LJ, et al. Outcomes over the first two years of treatment with mepolizumab in severe asthma. Eur Respir J. 2021. PMID: 34711539. doi:10.1183/13993003.01313-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。